PBM Reporting Transparency Act

Plain-English Summary: PBM Reporting Transparency Act

This bill focuses on Pharmacy Benefit Managers (PBMs) — companies that act as middlemen between drug manufacturers, insurance plans, and pharmacies. PBMs negotiate drug prices and decide which medications are covered under health insurance plans. Currently, there is limited public visibility into how these companies operate, what deals they make, and how they affect drug costs. Based on its title, this bill would require PBMs to report more detailed information about their business practices and financial arrangements, making that information more accessible to regulators and potentially the public.

The bill would likely affect a wide range of Americans, particularly those who rely on prescription drug coverage through their employer-sponsored health insurance, Medicare, or Medicaid. Patients, employers, and insurers have long raised concerns that PBM practices — such as keeping rebates from drug manufacturers — can contribute to higher out-of-pocket drug costs. By requiring greater transparency in reporting, the bill aims to shed light on where money flows in the prescription drug supply chain.

The legislation has been introduced in the Senate and referred to the Senate Finance Committee, which oversees healthcare and tax policy. It is currently in an early stage of the legislative process. Greater transparency requirements, if passed, could help lawmakers, employers, and consumers better understand and potentially address the role PBMs play in determining prescription drug prices.